L-697,661 is a non-nucleoside analogue with potent, selective inhibitory activity against the reverse transcriptase of human immunodeficiency virus type 1 (HIV-1).
evaluation of viral isolates for the emergence of resistance. Participants received 12 weeks of either placebo, 25 mg twice a day, 100 mg three times a day, or 500 mg twice a day of L-697,661, or zidovudine, 100 mg five times a day. Mean logarithmic reciprocal titers of plasma virus in patients takng either L-697,661 or zidovudine decreased by week 4 oftherapy; for L-697,661 recipients these changes were dose-dependent and, at the highest dose tested, were comparable in magnitude to those seen with zidovudine. Viral suppression induced by L-697,661 persisted through 8 weeks of treatment but decreased by week 12. This rebound paralleled emergence of viral isolates showing resistance to L-697,661. We conclude that although L-697,661 has potent antiretroviral activity in vivo, its utility may be compromised by rapid emergence of L-697,661-resistant virus. Plasma viremia is a highly sensitive technique affording considerable utility in the early testing ofsuch agents.
In this second decade of the human immunodeficiency virus type 1 (HIV-1) pandemic, considerable uncertainty still remains concerning the appropriate timing for introduction of antiretroviral therapy in patients with only mild to moderate immunodeficiency. One major reason for this has been the paucity of Non-plasma viremic individuals were randomly distributed throughout all five groups, as were zidovudine-naive participants (Table 2 ). Data were analyzed for all 58 participants completing a minimum of 12 weeks on study. The remaining individuals either dropped off study because of toxicity prior Fig. 2 . Mean CD4+ percentages for zidovudine and 500 mg BID L-697,661 recipients rose slightly relative to baseline over the 12-week study period; however, these differences were of insufficient magnitude to achieve statistical significance. Changes in absolute CD4+ counts also did not change significantly during this period (data not shown).
The number of participants with detectable serum p24 antigen in each group was too low to assess statistical changes in this parameter over time (data not shown). In the zidovudine treatment arm, for example, only 2 of 11 (18%) recipients entered with detectable antigen. Fig. 3 shows the effect of either L-697,661 or zidovudine therapy upon serum f$2-microglobulin levels. Zidovudine recipients showed statistically significant differences (P < 0.001) in mean P2-microglobulin levels by 8 comparably resistant isolates were isolated from patients on the intermediate dose of L-697,661, and none was isolated from low-dose L-697,661, zidovudine, or placebo recipients.
Only one viral isolate from this cohort showed relative zidovudine resistance by week 12 of study; this occurred in a zidovudine recipient who entered the study with a history of several months of prior zidovudine use.
DISCUSSION
Development of more potent, specific, and less toxic inhibitors of HIV-1 remains a major goal of current antiretroviral strategies. One of the most promising developments over the past 2 years was the introduction into clinical testing of several different nonnucleoside reverse transcriptase inhibitors (8, 9) . These agents do not require metabolic activation and, in certain cell lines, are up to 100-fold more potent than zidovudine in inhibiting propagation of laboratory strains of HIV-1 (1). They also display antiretroviral synergy with nucleoside analogues, suggesting a possible role in combination therapy in addition to their potential as monotherapeutic agents (10 Unfortunately, therapy with L-697,661 selects for rapid emergence of mutant strains of HIV-1 with decreased sensitivity to its antiviral effects. This occurred within only 12 weeks of therapy, was associated with a lessened effect on plasma virus suppression, and may also have been more common at the higher doses of L-697,661 tested. The latter argues for the emergence of resistant HIV-1 under direct selective pressure from the drug. Previous in vitro studies have suggested that stable mutations in one or two key amino acids (i.e., positions 103 and 181) of the reverse transcriptase of HIV-1, distinct from those associated with zidovudine or didanosine resistance, likely confer this resistance pattern (2) .
Our findings also dampen hopes that, as in the case of zidovudine resistance (11) , viral resistance to L-697,661 perhaps might be slower to develop in early patients than in those with more advanced disease. It also argues against the notion that a prolonged period of silent viral "latency" exists in such patients; in contrast, there must exist a rapidly replicating pool of virus capable of responding quickly to selective pressures induced by drug therapy. Presumably resistance patterns derived from plasma virus provide only a small measure of corresponding changes in viral turnover and mutation occurring within lymph nodes and other major sites of viral replication (12) .
It is conceivable that with better formulations or higher doses of non-nucleoside analogues, steady-state plasma concentrations of drug could be achieved that remain above the As the alarming toll of HIV-1 infection only continues to grow, the search for newer agents with the promise of enhanced potency assumes an ever greater importance. As such agents are identified, it becomes a legitimate concern of patients and physicians alike that, without sacrificing rigor, early virologic assessment of these drugs is completed as rapidly as technically feasible, hastening into expanded clinical testing those therapies that appear well-tolerated and that provide some early indications of possible efficacy. Quantitative plasma culture offers promise in terms of improved sensitivity and in applicability to an expanded population base, especially one in whom strict reliance upon more traditional endpoints has come under increasing challenge.
